🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Relapsed CLL

A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies NCT05908409Phase 1, Phase 211 sites📍 Santander📍 Salamanca📍 Barcelona IDP Discovery Pharma S.L. · Tests: IDP-121 Q702 for the Treatment of Patients With Hematologic Malignancies NCT06712810Phase 12 sites📍 Scottsdale📍 Rochester Mayo Clinic · Tests: Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine, Cyclophosphamide, Bone Marrow Cell Transplant Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies NCT06037018Phase 11 site📍 Tianjin CytoCares Inc · Tests: CC312 A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma NCT06588478Phase 2131 sites📍 Chandler📍 Duarte📍 Irvine Loxo Oncology, Inc. · Tests: Pirtobrutinib Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) NCT06644183Phase 1, Phase 21 site📍 Boston Jennifer R. Brown, MD, PhD · Tests: Roginolisib, Venetoclax, Rituximab A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies NCT06528301Phase 19 sites📍 Duarte📍 Chicago📍 Grand Rapids Umoja Biopharma · Tests: UB-VV111, rapamycin CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia NCT04704323Phase 14 sites📍 Boston📍 Durham📍 Madrid Catapult Therapeutics · Tests: CAP-100 A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting NCT06788639n/a1 site📍 Milwaukee Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Tests: Lisocabtagene maraleucel Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) NCT03986034Phase 21 site📍 Bethesda National Heart, Lung, and Blood Institute (NHLBI) · Tests: During Venetoclax Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. NCT04223765Phase 11 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: CAR.k.28, Fludarabine, Cyclophosphamide, Bendamustine Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma NCT06839053Phase 21 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Gastrointestinal Endoscopy, Rituximab Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma NCT06859008Phase 11 site📍 Duarte City of Hope Medical Center · Tests: Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography A Study of APG-3288 in Relapsed/Refractory Blood Cancers NCT07424833Phase 16 sites📍 Los Angeles📍 Jacksonville📍 Grand Rapids Ascentage Pharma Group Inc. · Tests: APG-3288 Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR NCT03676504Phase 1, Phase 22 sites📍 Heidelberg📍 Heidelberg University Hospital Heidelberg · Tests: CD19.CAR T Cells, Fludarabine, Cyclophosphamide Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual… MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab NCT07024706Phase 247 sites📍 Boston📍 Charlotte📍 Charlotte AstraZeneca · Tests: Acalabrutinib, Venetoclax Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial NCT04941716Phase 21 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Acalabrutinib, Venetoclax, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL NCT05963217Phase 11 site📍 Toronto University Health Network, Toronto · Tests: TBI-2001, Cyclophosphamide, Fludarabine A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT06973187Phase 3217 sites📍 Birmingham📍 Phoenix📍 Irvine BeOne Medicines · Tests: Tacabrutideg, Pirtobrutinib A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies NCT04830137Phase 116 sites📍 Duarte📍 Orange📍 San Francisco Nurix Therapeutics, Inc. · Tests: NX-2127 A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies NCT05131022Phase 162 sites📍 Duarte📍 San Francisco📍 Denver Nurix Therapeutics, Inc. · Tests: NX-5948 Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) NCT07225439Phase 12 sites📍 Cleveland📍 Cleveland Paolo Caimi, MD · Tests: Allogeneic NK cells, Rituximab, Tafasitamab, Interleukin-2, Fludarabine/cyclophosphamide Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies NCT05705570Phase 11 site📍 São Paulo Nelson Hamerschlak · Tests: Cyclophosphamide, Fludarabine, Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day… CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies NCT04186520Phase 1, Phase 21 site📍 Milwaukee Medical College of Wisconsin · Tests: 8/12-Day Production of Car-T Cells, 8/12-Day Production of Cryopreserved Car-T Cells, 12-Day Production of Car-T Cells A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia NCT05091424Phase 131 sites📍 Rochester📍 New York📍 Columbus Hoffmann-La Roche · Tests: Mosunetuzumab, Tocilizumab, Venetoclax, Rituximab Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL NCT05702853Phase 1, Phase 21 site📍 Charleston Medical University of South Carolina · Tests: Cyclophosphamide injection, Fludarabine Injection, CD19-CD34t metabolically programmed CAR transduced T-cells CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL NCT06346912EARLY Phase 11 site📍 Hangzhou Zhejiang University · Tests: CD19-BAFF Targeted CAR T-cells Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) NCT06533579Phase 1, Phase 211 sites📍 Duarte📍 Los Angeles📍 Denver Vironexis Biotherapeutics Inc. · Tests: Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101, Dose Level 4, VNX-101 Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma NCT07532525Phase 11 site📍 Ann Arbor University of Michigan Rogel Cancer Center · Tests: Biospecimen Collection, Pomalidomide
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy